X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EPI-7386 (masofaniten) is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. It is currently being studied in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
ESSA will conduct a Phase 1 trial evaluating the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of EPI-7386 when administered in combination with either apalutamide or abiraterone acetate plus prednisone in patients with prostate cancer.
Lead Product(s): Masofaniten,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 12, 2023
Details:
EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. It is currently being studied for CRPC whose tumors have progressed on standard-of-care therapies.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. EPI-7386 is being studied in men with castration-resistant prostate cancer ("CRPC") whose tumors have progressed on standard-of-care therapies.
Lead Product(s): Masofaniten,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
EPI-8207, an ANITAC, shows robust potency degrading AR, including AR splice variants and clinically relevant AR mutants that can potentially drive disease progression in patients with castration-resistant prostate cancer ("CRPC").
Lead Product(s): EPI-8207
Therapeutic Area: Oncology Product Name: EPI-8207
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
The initial data from 36 patients demonstrate that EPI-7386 was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily pretreated group of patients.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
The preclinical results for EPI-7386, demonstrated that ANITAC degraders utilize the ubiquitin proteasome system and can degrade many forms of AR including full length, mutant and splice variants which are often expressed in CRPC patients.
Lead Product(s): Masofaniten
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Results from the research indicated that EPI-7386 has an IC50 of 421 nM in LNCaP reporter assays, which is a range that is comparable to most LBD inhibitors; however, this agent differs from known agents in that its antitumor activity was maintained in CRPC models.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor.
Lead Product(s): Masofaniten
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
